Results 11 to 20 of about 3,459,561 (335)

Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension

Emerging Microbes and Infections, 2020
The dysfunction of the renin-angiotensin system (RAS) has been observed in coronavirus infection disease (COVID-19) patients, but whether RAS inhibitors, such as angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II type 1 receptor blockers
Guohui Xiao, Zhaoqin Wang, Guoliang Zhang   +2 more
exaly   +3 more sources

Renin inhibitors versus angiotensin converting enzyme (ACE) inhibitors for primary hypertension. [PDF]

Cochrane Database Syst Rev, 2020
BACKGROUND Renin inhibitors (RIs) reduce blood pressure more than placebo, with the magnitude of this effect thought to be similar to that for angiotensin converting enzyme (ACE) inhibitors. However, a drug's efficacy in lowering blood pressure cannot be
Wang GM, Li LJ, Tang WL, Wright JM.
europepmc   +2 more sources

The Yin and Yang of ACE/ACE2 Pathways: The Rationale for the Use of Renin-Angiotensin System Inhibitors in COVID-19 Patients

Cells, 2020
The article describes the rationale for inhibition of the renin-angiotensin system (RAS) pathways as specific targets in patients infected by SARS-CoV-2 in order to prevent positive feedback-loop mechanisms.
Loris Zamai
doaj   +2 more sources

Hyperkalemia and Renin–Angiotensin–Aldosterone System Inhibitors Dose Therapy in Heart Failure With Reduced Ejection Fraction [PDF]

Cardiac Failure Review, 2019
Renin–angiotensin–aldosterone system inhibitors (RAASi) are known to improve outcomes in patients who have heart failure with reduced ejection fraction (HFrEF).
Giuseppe MC Rosano, Ilaria Spoletini, Cristiana Vitale, Stefan Agewall   +3 more
doaj   +2 more sources

Renin–angiotensin–aldosterone pathway modulators in chronic kidney disease: A comparative review

Frontiers in Pharmacology, 2023
Chronic kidney disease presents a health challenge that has a complex underlying pathophysiology, both acquired and inherited. The pharmacotherapeutic treatment options available today lower the progression of the disease and improve the quality of life ...
Saeed Alshahrani
doaj   +2 more sources

Aliskiren – an orally active renin inhibitor. Review of pharmacology, pharmacodynamics, kinetics, and clinical potential in the treatment of hypertension

Vascular Health and Risk Management, 2008
Kristina AllikmetsDepartment of Drug Development and Medical Affairs, Nycomed Group, Roskilde, DenmarkAbstract: The importance of renin-angiotensin-aldosterone system (RAAS) in diseases such as hypertension, congestive heart failure and chronic renal ...
Kristina Allikmets
doaj   +1 more source

Development, evaluation and application of 3D QSAR Pharmacophore model in the discovery of potential human renin inhibitors

BMC Bioinformatics, 2011
Background Renin has become an attractive target in controlling hypertension because of the high specificity towards its only substrate, angiotensinogen.
John Shalini, Thangapandian Sundarapandian, Arooj Mahreen, Hong Jong, Kim Kwang, Lee Keun   +5 more
doaj   +2 more sources

Renin inhibition with aliskiren in hypertension: focus on aliskiren/hydrochlorothiazide combination therapy

Vascular Health and Risk Management, 2008
Kalathil K SureshkumarDivision of Nephrology and Hypertension, Allegheny General Hospital, Pittsburgh, Pennsylvania, USAAbstract: Hypertension is a major risk factor for the development of cardiovascular and renal disease.
Kalathil K Sureshkumar
doaj   +1 more source

Renin inhibitors. [PDF]

J Clin Hypertens (Greenwich), 2011
Fisher ND, Meagher EA.
europepmc   +3 more sources

Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial

The Lancet Respiratory Medicine, 2021
Background Biological considerations suggest that renin–angiotensin system inhibitors might influence the severity of COVID-19. We aimed to evaluate whether continuing versus discontinuing renin–angiotensin system inhibitors (angiotensin-converting ...
Jordana B. Cohen, T. Hanff, Preethi William, N. Sweitzer, Nelson R Rosado-Santander, Carola Medina, Juan E Rodriguez-Mori, N. Renna, T. Chang, V. Corrales-Medina, J. Andrade-Villanueva, Alejandro Barbagelata, Roberto Cristodulo-Cortez, Omar A Díaz-Cucho, J. Spaak, C. Alfonso, Renzo Valdivia-Vega, Mirko Villavicencio-Carranza, Ricardo J Ayala-García, Carlos A Castro-Callirgos, L. González-Hernández, Eduardo F Bernales-Salas, Johanna C Coacalla-Guerra, Cynthia D Salinas-Herrera, L. Nicolosi, Mauro Basconcel, J. B. Byrd, Tiffany Sharkoski, Luis E Bendezú-Huasasquiche, J. Chittams, Daniel L. Edmonston, C. Vasquez, J. Chirinos   +32 more
semanticscholar   +1 more source